Fosun Pharmaceutical (02196.HK): Injection FXR0906 Approved for Clinical Trials
NewTimeSpace News: On 15 July 2026,Fosun Pharmaceutical(02196.HK) issued an announcement that its controlling subsidiaryFosun Pharmaceutical(Shenzhen) has received an approval reply from the National Medical Products Administration (NMPA), greenlighting clinical trials of Injection FXR0906 for hypertriglyceridemia.
FXR0906 is a liver-targeted siRNA therapeutic licensed in by Fosun Pharma. It suppresses the expression of the APOC3 gene via RNA interference technology to reduce serum triglyceride levels. The Group holds exclusive rights to research, develop, register, manufacture and commercialize the drug in Chinese mainland, Hong Kong and Macao.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- FOSUN PHARMA (02196.HK): Registration application for new specification of HLX14 denosumab biosimilar accepted by NMPA
- FOSUN PHARMA (02196.HK): FXS5626 Approved for Phase II/III Trial in Non-Segmental Vitiligo
- FOSUN PHARMA (02196.HK): Sells 6% Stake in India's Gland Pharma for Approximate USD 294 Million
- FOSUN PHARMA (02196.HK): Licensed drug weliteitumab injection (GR1803) granted conditional approval for relapsed or refractory multiple myeloma
- FOSUN PHARMA (02196.HK): Repurchases 217,000 H shares for approximately HKD 3.587 million
